Holen Sie sich die Stockscreener-App
2.15
0.46%
-0.01
Vorhandelsmarkt:
2.16
0.01
+0.47%
Schlusskurs vom Vortag:
$2.16
Offen:
$2.16
24-Stunden-Volumen:
152.14K
Relative Volume:
0.55
Marktkapitalisierung:
$86.67M
Einnahmen:
$2.70M
Nettoeinkommen (Verlust:
$5.53M
KGV:
19.55
EPS:
0.11
Netto-Cashflow:
$-10.55M
1W Leistung:
-9.28%
1M Leistung:
-5.29%
6M Leistung:
-13.31%
1J Leistung:
-37.86%
1-Tages-Spanne:
$2.085
$2.1697
1-Wochen-Bereich:
$2.085
$2.37
52-Wochen-Spanne:
$2.00
$3.67
Oramed Pharmaceuticals Inc Stock (ORMP) Company Profile
Firmenname
Oramed Pharmaceuticals Inc
Sektor
Branche
Telefon
646-844-1164
Adresse
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Vergleichen Sie ORMP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORMP
Oramed Pharmaceuticals Inc
|
2.15 | 86.67M | 2.70M | 5.53M | -10.55M | 0.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.35 | 123.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
723.47 | 79.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
624.94 | 37.97B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.20 | 31.74B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
259.70 | 27.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Oramed Pharmaceuticals Inc Stock (ORMP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-01-12 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-02-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-20 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-02-09 | Eingeleitet | National Securities | Buy |
| 2020-12-03 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-11 | Eingeleitet | Aegis Capital | Buy |
| 2019-09-11 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-12-11 | Fortgesetzt | B. Riley FBR, Inc. | Buy |
| 2016-05-26 | Bestätigt | FBR Capital | Outperform |
| 2015-12-01 | Bestätigt | H.C. Wainwright | Buy |
| 2015-11-19 | Eingeleitet | FBR Capital | Outperform |
| 2015-04-13 | Fortgesetzt | MLV & Co | Buy |
| 2014-01-30 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Bestätigt | Aegis Capital | Buy |
| 2014-01-08 | Eingeleitet | MLV & Co | Buy |
| 2013-12-03 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Oramed Pharmaceuticals Inc Aktie (ORMP) Neueste Nachrichten
Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to Sell at StockNews.com - MarketBeat
227,239 Shares in Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Acquired by Peapod Lane Capital LLC - MarketBeat
OraTech to pioneer oral insulin with $75 million investment - MSN
Oramed Pharmaceuticals : Ancillary Agreement Completion Protocol and Supplemental Agreement - Marketscreener.com
Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Simply Wall St
Oramed Pharm Amends Joint Venture for OraTech Launch - TipRanks
Oramed (ORMP) Stock Skyrockets Amid JV Development Plans - Stocks Telegraph
Oramed announces spinoff of protein drug technology - MSN
OraTech to pioneer oral insulin with $75 million investment By Investing.com - Investing.com South Africa
Oramed Pharmaceuticals Forms Joint Venture to Commercialize Oral Insulin; Shares Rise - Marketscreener.com
Oramed Pharmaceuticals to Spin Off Its Protein Oral Delivery Technology - Contract Pharma
Oramed stock soars on spinoff plans (ORMP:NASDAQ) - Seeking Alpha
Oramed Announces Joint Venture To Develop And Commercialize Oral Insulin -February 11, 2025 at 09:17 am EST - Marketscreener.com
Oramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin - PR Newswire
Charting the Course: Viking Therapeutics Inc’s VKTX Stock Prospects - The InvestChronicle
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Rating Lowered by StockNews.com - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Cross Below Two Hundred Day Moving Average – Here’s Why - Defense World
Oramed Pharmaceuticals Extends Maturity Date of Senior Secured Promissory Note in Recent Amendment - Defense World
Oramed Pharmaceuticals extends loan maturity, acquires Scilex shares - Investing.com
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025 - The Manila Times
Scilex Holding Company Announces Extension of the Maturity - GlobeNewswire
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Sees Significant Decrease in Short Interest - MarketBeat
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to “Hold” at StockNews.com - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Raised to Hold at StockNews.com - MarketBeat
Oramed Pharmaceuticals Reports Deferral and Consent Agreement for Tranche B Senior Secured Convertible Note - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to Sell Rating by StockNews.com - MarketBeat
ADVANZ PHARMA (OTCMKTS:CXRXF) versus Oramed Pharmaceuticals (NASDAQ:ORMP) Critical Comparison - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com - MarketBeat
StockNews.com Upgrades Oramed Pharmaceuticals (NASDAQ:ORMP) to “Hold” - Defense World
Oramed Pharmaceuticals (NASDAQ:ORMP) Upgraded to Hold at StockNews.com - MarketBeat
Oramed secures $13.2 million payment from Scilex - Investing.com
Oramed secures $13.2 million payment from Scilex By Investing.com - Investing.com UK
Palo Alto pharmaceutical company secures $17M - The Business Journals
Scilex Holding Company Announces Early Installment Payment on its Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation - The Manila Times
Scilex Holding Company Announces Early Installment Payment - GlobeNewswire
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt - The Eastern Progress Online
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Above 50 Day Moving AverageHere's What Happened - MarketBeat
3 US Penny Stocks With Market Caps Above $40M - Yahoo Finance
ORMP: Preparations for New Phase 3 Trial Advance, While ORMP Leverages Balance Sheet Through Recent Agreements - Yahoo Finance
Oramed Pharmaceuticals (NASDAQ:ORMP) Shares Pass Below 200-Day Moving AverageTime to Sell? - MarketBeat
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Stock Holdings Lifted by BML Capital Management LLC - MarketBeat
Oramed Pharmaceuticals : INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTSAS OF SEPTEMBER 30, 2024 - Marketscreener.com
Finanzdaten der Oramed Pharmaceuticals Inc-Aktie (ORMP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.53%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):